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Retinal ischemia is a major cause of blindness worldwide. It is associated with various
disorders such as diabetic retinopathy, glaucoma, optic neuropathies, stroke, and other
retinopathies. Retinal ischemia is a clinical condition that occurs due to lack of appropriate
supply of blood to the retina. As the retina has a higher metabolic demand, any hindrance
in the blood supply to it can lead to decreased supply of oxygen, thus causing retinal
ischemia.The pathology of retinal ischemia is still not clearly known.To get a better insight
into the pathophysiology of retinal ischemia, the role of animal models is indispensable.The
standard treatment care for retinal ischemia has limited potential. Transplantation of stem
cells provide neuroprotection and to replenish damaged cells is an emerging therapeutic
approach to treat retinal ischemia. In this review we provide an overview of major animal
models of retinal ischemia along with the current and preclinical treatments in use.
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INTRODUCTION
The term“ischemia” implies reduction in the blood supply to a tis-
sue resulting in insufﬁciency to meet the metabolic requirements.
Thus, retinal ischemia is the clinical conditionwhen the blood sup-
ply to the retina is obstructed. The retina is an extension of central
nervous system (CNS) and thus shares many embryological, func-
tional, and anatomical characteristics with brain. The response to
ischemia in retinal neurons is similar to those in other parts of
CNS. Nevertheless, retina is more resistant to ischemic injury than
the brain (Tso and Jampol, 1982).
As far as the blood supply to the retina is concerned, the mam-
malian retina has a dual circulation system. The major portion of
blood supply goes to the choroid, i.e., 65–85% of the total supply,
whereas the remaining goes to the retina through central retinal
artery, which originates from ophthalmic artery (Henkind et al.,
1979). Figure 1 depicts the blood supply to the eye. The extent
of retinal ischemia and the region of retina affected depends on
the blood supply that is obstructed (Saint-Geniez and D’Amore,
2004). The retina has a high metabolic demand. Any hindrance in
the blood supply affects the exchange of substrates and products,
leading to many morphological and functional changes in retina.
The pathophysiology of retinal ischemia is not completely known
but involves imbalance in ion transport, changes in neurotrans-
mitter levels, oxidative stress, and ﬁnally cell death. Thus, there
is a need to study the pathophysiology involved so that better
therapeutic agents can be tested. As retina can be studied non-
invasively the investigations into retinal ischemia may lead to a
better understanding of cerebral ischemia.
NEED FOR ANIMAL MODELS
Although humans and animals have varying phenotype, they
share strikingly common physiological and anatomical details.
Therefore, to understand the human physiology and to test new
treatments through preclinical investigations, animal experimen-
tation has always been a core of basic and clinical research. The
importance of developing animal models for retinal ischemia
originates from the limitations found in the use of in vitro mod-
els. Retinal ischemia at molecular and biochemical levels can be
studied in depth using an in vitro model of ischemia but the patho-
physiological details can only be understood using an appropriate
animal model. An ideal animal model for retinal ischemia should
have parallelism with humans at anatomical, vascular, and retinal
levels besides offering ease in handling and manipulation.
ANIMAL MODELS OF RETINA ISCHEMIA
ELEVATION OF INTRAOCULAR PRESSURE
The model often used to cause retinal ischemia is by increasing
intraocular pressure (IOP). This model involves elevation of the
IOP above the systemic arterial pressure for a ﬁxed duration of
time (Peachey et al., 1993).High IOP results in global ischemia as it
hampers the blood supply from both uveal and retinal circulation.
In rodents, different groups have shown that IOP-induced retinal
ischemia mimics the features observed in human central reti-
nal artery occlusion (CRAO) and primary open angle glaucoma
(Smith and Baird, 1952; Buchi et al., 1991).
The animal model of retinal ischemia model was ﬁrst described
by Smith andBaird (1952) andwas further validated by Flower and
Patz (1971) in cats. In rodents, the elevated IOP-induced retinal
ischemia injury was induced in rats by Buchi et al. (1991). In all
these studies, the IOP was increased through cannulation of the
anterior chamber with a 26-gauge needle connected to an ele-
vated chamber containing normal saline. The IOP was raised to
110 mm Hg. This method has been used in a wide range of exper-
iments to study the alteration in protein expression, ion channel
imbalance, excitotoxicity in various animal models (Hirrlinger
et al., 2010; Joachim et al., 2011). Ji et al. (2005) used this model
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FIGURE 1 |The figure depicting the circle of Zinn-Haller and the blood
supply to eye (Hayreh, 1963).
in mice to investigate the mechanism behind the retinal ganglion
cell death due to retinal ischemia.
The advantages of using this model are that it is temporary
and reversible, easy to create, and reproduce and there is minimal
requirement of surgery or special equipments. But there is a limi-
tation to this model that the elevated IOP can itself cause damage
and hence, lead to incorrect interpretation of the data (Peachey
et al., 1993).
MIDDLE CEREBRAL ARTERY OCCLUSION
It has been reported that the cerebral stroke incidents are invariably
accompanied with temporary (amaurosis fugax) or permanent
vision loss. A purely vascular model of retinal ischemia is the mid-
dle cerebral artery occlusion (MCAO). As the ophthalmic artery
which is the source of blood supply to the inner retina origi-
nates proximal to the origin of middle cerebral artery (MCA),
any hindrance in the blood ﬂow in MCA obstructs the ﬂow to
the ipsilateral retina. This method involves occlusion of blood
supply by the use of a ﬁlament inserted through external carotid
artery (ECA) and internal carotid artery (ICA) and advanced into
the MCA.
This procedure was ﬁrst time demonstrated by Block et al.
(1997) in rats that led toMCAO induced retinal ischemia. Later the
same model was used to depict damage to retina through MCAO
in mice (Steele et al., 2008). This model is a non-invasive and
does not disrupt the blood–retina barrier or cause any mechanical
damage to the retina (Kaja et al., 2003). The MCAO model has
other advantages including reproducibility making it permissive
for reperfusion related investigations.
CHRONIC CAROTID OCCLUSION
Retinal ischemia can also be caused by carotid artery disease in
humans. This model was ﬁrst induced by Block et al. (1992) in
rats in order to show that the bilateral common carotid artery
occlusion in rats causes functional damage to the retina. The elec-
troretinogram studies have also shown a decrease in amplitude of
b-wave 7 days after the bilateral carotid artery occlusion or two-
vessel occlusion (2VO). The b-wave represents the bipolar and
Muller cell activity (Barnett and Osborne, 1995). Not only func-
tional, 2VO model also causes structural damage to the retina.
In another study in rats, Lavinsky et al. (2006) showed that in
the animals that showed functional damage, the retinal thickness
was found to be decreased and the layers that are most affected
included inner and outer plexiform layers.
The 2VO model for retinal ischemia leads to permanent occlu-
sion without any reperfusion. Due to collateral blood circulation
partial blood supply to retina is retained through Circle of Willis
leading to variable retinal damage.
PHOTOTHROMBOSIS OF RETINAL VESSELS
The photothrombosis or photocoagulation induced retinal
ischemiamodel is a simple and non-invasivemethod. It is compar-
atively a newmethod toperformvessel occlusion. Thismethodwas
ﬁrst described in adult rat retina by Mosinger and Olney (1989),
where the authors injected Rose Bengal, a photosensitive dye intra-
venously and then exposed the retina to light of a ﬁxed wavelength
(550 nm) leading to photothrombosis. Miller et al. (1994) used
this same method in a non-human primate model, cynomol-
gus monkey (Macaca fascicularis), where a laser at 577 nm was
used for causing occlusion. Buchi et al. (1994) used this model to
study morphological and histological changes in retina. Schimdt-
Kastner also used Photothrombosis to induce ischemia in rat
retina and showed the ganglion cell death (Schmidt-Kastner and
Eysel, 1994). Another photosensitive dye, apart from Rose Bengal,
that can be used in this model, is chloro-aluminum sulfonated
phthalocyanine (Kliman et al., 1994).
Like any other method, this too has its own advantages and dis-
advantages. Photothrombosis leads to variability in retinal damage
and hence irregular damage due to variation in light exposure. It
leads to permanent ischemia and can therefore not be used to
study damage due to reperfusion. This method results in damage
due to free-radicals.
OCCLUSION OF CENTRAL RETINAL ARTERY
The central retinal artery is the ﬁrst intraorbital branch of oph-
thalmic artery. The CRAO causes complete inner retinal ischemia.
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In humans, the clinical features were ﬁrst described by von Graefe
(1859). The CRAO model has been used to induce retinal ischemia
in different species. Hayreh induced transient CRAO in rhe-
sus monkeys by clamping the central retinal artery for different
time durations. This study also showed that the damage induced
depends on the tolerance time for the particular species (Hayreh
et al., 1980). Zhang et al. (2005) created this model in rats by intra-
venous injection of Rose Bengal and treating the animals with
green laser. This model is used to study the pathways involved
in transient retinal ischemia by mimicking the clinical features
of CRAO in humans. In another study in CRAO model in rhesus
monkeys, amino acid proﬁlingwas done to evaluate the role of glu-
tamate excitotoxicity in ischemia (Kwon et al., 2005). The mouse
model showing similar changes as human CRAO has been gener-
ated, where central retinal artery was occluded by laser photoacti-
vation of Rose Bengal. The occlusion of 6–24 h showed molecular
and histological changes (Goldenberg-Cohen et al., 2008). CRAO
can also be achieved by another method which leads to ischemia –
reperfusion model. In this model a suture is placed behind the
eye globe and then obstructing the blood ﬂow by pressing the
tube through which both ends of suture are passed (Prasad et al.,
2010).
ENDOTHELIN ADMINISTRATION
Endothelin-1 or ET-1 is a 21 amino acid long peptide with
vasoconstrictor activity. It was ﬁrst puriﬁed and characterized
in 1988 from the conditioned medium of cultures of porcine
aortic endothelial cells (Yanagisawa et al., 1988). In humans,
cardiovascular disease, renal, and ocular disorders have been
associated with endothelin-1. The vasoconstrictor activity of
endothelin has been demonstrated in retinal arteries in rats. In
a study by Bursell et al. (1995) an approximate 17% reduc-
tion in diameter after 10−7 M concentration of ET-1 was shown.
Sakaue et al. also studied the effect of endothelin on the reti-
nal vessels after intravitreal administration of ET-1 in rabbit
eyes. The authors showed a dose-dependent response, where
the concentration of 10−6 M caused vasoconstriction and lower
concentrations caused vasodilation ﬁrst with vasoconstrictions
later, leading to hypoxia and retinal ischemia (Sakaue et al.,
1992; Sato et al., 1993; Takei et al., 1993). In another study,
ET-1 administration was used to obstruct the central retinal
artery causing ganglion cell loss in retina (Masuzawa et al.,
2006).
No problems such as inﬂammation or infection are associated
with this model, but this has a limitation of ET-1 dose. Also it may
show some undesirable effect due to systemic circulation to other
tissues.
CURRENT AND POTENTIAL THERAPEUTIC STRATEGIES FOR
RETINAL ISCHEMIA
Current treatments for retinal ischemia involve recovery of the
blood circulation in retina that will prevent further damage and
permanent vision loss. Combination of strategies are being used to
treat retinal ischemia including intravitreal or retinal vein admin-
istration of anticoagulants such as tissue-plasminogen activator
(t-PA), hemodilution, pan-retinal laser photocoagulation, or anti-
VEGF antibodies (Lucentis or Avastin). Ischemic conditions in
retina have been shown to up-regulate the expression of vas-
cular endothelial growth factor or VEGF, a potent angiogenic
factor. This change in VEGF levels leads to retinal neovascular-
ization or growth of abnormal blood vessels. Neutralizing VEGF
through monoclonal antibodies has been shown to block neo-
vascularization. This technique was tested in a primate model of
retinal ischemia induced by laser. The study showed that VEGF
was inhibited in vivo when proteins containing human (Flt) or
mouse (Flk) VEGF receptors attached to IgG were administered
(Aiello et al., 1995). This showed almost complete inhibition of
neovascularization. Laser photocoagulation or pan-retinal laser
treatment is used to decrease the neovascularization or growth
of abnormal blood vessels, thus decreasing the damage to the
retina.
All these strategies that are being used have their own limi-
tations. The anticoagulants and vasodilators are effective only in
limited cases of retinal ischemia, such as CRAO patients, while the
laser treatment is effective only when given early (Rumelt et al.,
1999). This unavailability of effective treatment options has led
to development of various other neuroprotective agents. Other
possible therapeutic agents include NMDA receptor blockers or
inhibitors, catalase and thioredoxin (free-radical scavengers), cal-
cium channel blockers, and many others. These novel drugs and
chemical compounds have been tested in different animal mod-
els of retinal ischemia, showing positive outcome and potential as
future therapeutics. Various antagonists and blockers have been
demonstrated to reduce the damage caused through ischemia.
NMDA receptor antagonists have shown neuroprotective effect
in retinal ischemia animal models. Different NMDA receptor
blockers that have been tested in preclinical studies are dex-
tromethorphan, MK-801, memantine (Cao et al., 1994; Lam et al.,
1997; Osborne et al., 1999). Blockers of calcium channels have
also been tested in animal models and have shown to decrease
neurotoxicity (Melena et al., 1999). Retinal ischemia damage is
exacerbated by free-radicals. Free-radicals are generated by re-
oxidation of compounds during reperfusion and leads to oxidative
stress (Gilgun-Sherki et al., 2002). Thus, different free-radical
scavengers can be used for treatment. Rios et al. compared the free-
radical scavengers – SOD or superoxide dismutase and DMTU
or dimethylthiourea. In an IOP-induced retinal ischemia model
in rats, intravitreal administration of both the compounds has
shown to potential in recovery. In this model, DMTU led to
40% functional recovery while SOD treatment showed a 99%
recovery when assessed through electroretinogram (Rios et al.,
1999).
Apart from these, growth factors such as CNTF, bFGF,
NGF, BDNF, PEDF, HGF have been tested in retinal ischemia–
reperfusion models for therapeutic potential (Unoki and LaVail,
1994; Ogata et al., 2001; Shibuki et al., 2002). These therapeutic
agents have short half-life and thus require repeated administra-
tion resulting in side-effects. This limitation can be overcome by
the delivery of the gene of neurotrophic factors directly using
gene therapy. Viral vectors have been used successfully to trans-
fect cells in eye (Bennett et al., 1994; Flannery et al., 1997; Di
Polo et al., 1998). Wu et al. used recombinant Adeno-associated
virus (AAV) vector to transfer GDNF intravitreally in rats sub-
jected to elevated IOP. GDNF is a known neurotrophic factor
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that reduces ischemic injury (Wu et al., 2004). It has also been
shown in different studies that GDNF protects photoreceptors and
inhibits apoptosis. Another group of neuroprotectants that have
shown positive results in animal models by inhibiting apoptosis
are the inhibitors of apoptosis (IAP) which inhibit caspases. Most
tested IAP is the XIAP which blocks caspases 3, 7, and 9 (Dev-
eraux et al., 1997; Xu et al., 1999; Eberhardt et al., 2000; Holcik
et al., 2001; McKinnon et al., 2002; Petrin et al., 2003). Renwick
et al. reported that XIAP overexpression protects the retina from
transient ischemia induced by elevation of IOP in rats. In this
study the authors intravitreally administered AAV vector express-
ing XIAP and demonstrated structural and functional protection
in retinal ischemiamodel (Renwick et al., 2006). But it has a limita-
tion of being ineffective in the cases where retinal ischemia occurs
suddenly.
ROLE OF STEM CELL THERAPY IN RETINAL ISCHEMIA
The treatment strategies discussed in the previous section have
limited potential. Stem cells are an emerging branch used in the
treatment of a wide variety of disorders (Lenka and Anand, 2009).
The use of stem cells from different sources are being studied and
clinical trials are being carried out for disorders such as diabetes,
spinal cord injury, fractures, cardiovascular, and neurological dis-
orders. Replenishment of neuronal and retinal cells by stem cell
transplantation is therefore a promising approach to treat retinal
ischemia.
The stemcells have an ability to self-renewanddifferentiate into
specialized cells. They can act through various mechanisms. Stem
cells can induce angiogenesis and thus, increase vascularization.
Stem cells can also enhance the endogenous repair mechanisms,
reduce inﬂammation, and release trophic factors. In the case of
retinal ischemia, the eye is easily accessible for transplantation of
stem cells. Thus, the stem cell therapy has a huge potential to
restore visual function in case of retinal ischemia (Cogliati and
Swaroop, 2009).
Stem cells from various sources have been used for treatment.
Most commonly used are the stem cells from the bone-marrow
as they are easier to obtain. Two types of cell population is
present in the bone-marrow – hematopoietic progenitor cells and
hematopoietic stem cells. The sub-population of hematopoietic
stemcells has been shown todifferentiate into lineage-negative and
lineage-positive sub-types. This division is according to their abil-
ity to differentiate. The cells in lineage-negative fraction can lead to
vascular endothelial cells or the endothelial precursor cells after the
differentiation. These progenitor cells can then mobilize from the
bone-marrow and home to target sites of angiogenesis in differ-
ent injuries. Bone-marrow mesenchymal stem cells (BM-MSCs)
differentiate into retinal neural cells in vivo and in vitro, and when
implanted at a site of injury in experimental animal models, they
show the ability to migrate to the injury site, initiate tissue repair,
and restore function (Goes et al., 2008).
Another source of stem cells for the therapeutic purposes is
those obtained from the early embryos. These embryonic stem
cells have two characteristic properties, their ability to replicate
indeﬁnitely and their pluripotency. Thus the embryonic stem cells
can differentiate into various cell types. These cells have also been
tested in the cerebral ischemia model, showing structural as well
as functional recovery (Wei et al., 2005). Various research groups
have shown the potential of these stem cells in neurodegenera-
tive diseases including retinal damage. The use of embryonic stem
cells for transplantation has its own limitations. The foremost is
the ethical concerns over its use and secondly there is a risk of
immune rejection. To overcome these limitations, another stem
cell source from non-pluripotent cells was discovered. In 2006,
Takahashi and Yamanaka identiﬁed four transcription factors –
Oct3/4, Sox-2,Klf-4, c-myc. These factors can reprogram the DNA
leading to the formation of stem cells from a non-pluripotent
cell. These stem cells are known as induced pluripotent stem cells
or iPCs (Takahashi and Yamanaka, 2006). iPCs have been used
in various animal models and have shown to form different cell
types. In humans, iPCs have been isolated from the patients with
neurodegenerative disorders such as Parkinson’s disease, muscu-
lar dystrophy, amyotrophic lateral sclerosis (Dimos et al., 2008;
Park et al., 2008). iPCs have been used to generate human neu-
ronal cells, photoreceptors, and retinal pigmented epithelium cells
(Takahashi and Yamanaka, 2006; Hirami et al., 2009; Karumba-
yaram et al., 2009). Another source of stem cells that is being
tested as a potential therapy is the umbilical cord blood. It has
a large percentage of hematopoietic stem cells, higher than those
found in bone-marrow and also these cells show lesser immune
rejection.
Earlier the CNS was thought to be a non-renewable tissue in
mammals. Neural stem cells are normally found in the developing
CNS, but studies have shown that these are also present in adult
CNS. These cells are found in restricted region of CNS, such as hip-
pocampus, subventricular zone, spinal cord, and ependyma and
Table 1 | Advantages and limitations of different animal models of retinal ischemia.
Animal model Advantages Limitations
Elevation of intraocular pressure Temporary and reversible; easy to create and reproduce;
minimal requirement of surgery or special equipments
High IOP can cause damage
Middle cerebral artery occlusion Transient (can study reperfusion); reproducible Requires specialized skills; incomplete ischemia; alter
blood ﬂow to the brain
Chronic carotid occlusion Reproducible; easy Variable damage; permanent ischemia
Photothrombosis of retinal vessels Simple Variable degrees of exposure and variable damage;
permanent ischemia; free-radical damage
Occlusion of central retinal artery Complete retinal ischemia –
Endothelin administration No inﬂammation or infection Can enter systemic circulation
Frontiers in Neurology | Neuro-Ophthalmology May 2012 | Volume 3 | Article 75 | 4
Minhas et al. Preclinical models to investigate retinal ischemia
can form astrocytes, neurons, and oligodendrocytes. The neural
stem cells were ﬁrst isolated from adult rat hippocampus (Palmer
et al., 1997). These cells have shown the ability to migrate and
differentiate into neuronal cells in retinal injury (Nishida et al.,
2000). But more studies need to be done to estimate the efﬁciency
of the neural stem cells.
The stem cell transplantation in retina has some limitations,
such as poor cell homing, cell migration, and integration. Thus,
many of the transplanted cells do not reach the retina. A study has
shown that only 1% of the cells transplanted intraocularly reach
the retina (Johnson et al., 2010).
CONCLUSION
Retinal ischemia is the clinical condition caused by insufﬁcient
supply of blood to retina and is found in many of the disorders.
Retina, like the CNS originates from the ectoderm. Thus, with
the use of animal models of retinal ischemia pathophysiology can
be studied and therapeutic agents can be tested. Each of the ani-
mal models described in this review has its own advantages and
limitations. Table 1 summarizes the advantages and limitations
of the retinal ischemia models discussed in this review. Thus, the
choice of animal models for pre-clinical testing will depend on the
research problem involved.
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